Soligenix, Inc. — Q3 2013 Form 10-Q
Reporting period: Three and nine months ended September 30, 2013. Soligenix is a clinical-stage biopharmaceutical company developing therapies for inflammatory diseases and biodefense products. Revenue was principally grant-funded; the company reported no product sales.
Key financial results
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Revenue | $312,491 | $931,627 | $1,845,123 | $2,341,896 |
| Gross profit | $66,627 | $169,999 | $327,654 | $407,367 |
| Gross margin | 21.3% | 18.2% | 17.8% | 17.4% |
| Research and development expense | $1,216,559 | $371,338 | $4,113,686 | $1,749,112 |
| Operating loss | $1,860,662 | $760,216 | $5,704,443 | $3,182,883 |
| Net loss | $6,559,856 | $758,966 | $11,052,427 | $3,177,599 |
| Basic and diluted loss per share | $0.34 | $0.07 | $0.78 | $0.29 |
- Cash and liquidity: Cash and cash equivalents were $6.58 million at September 30, 2013, up from $3.36 million at year-end 2012. Working capital was $5.67 million excluding the $9.98 million non-cash warrant liability.
- Cash flow: Nine-month operating cash use was $3.16 million, compared with $2.29 million in the prior-year period. Financing provided $6.40 million, principally from the public offering. Cash increased by $3.23 million during the period.
- Assets, liabilities and equity: Total assets were $7.65 million; current liabilities were $11.25 million, including the warrant liability. Shareholders’ equity was a deficit of $3.60 million. The filing does not report conventional borrowings or debt.
Material changes and unusual items
- Revenue fell 66% in Q3 and 21% for the nine-month period, primarily reflecting the timing of grant activity and related development work. Grant-funded costs also declined, leaving gross profit lower year over year.
- R&D expense increased 228% in Q3 and 135% year to date, mainly due to preparation for SGX942 and SGX203 clinical trials and the Intrexon collaboration. The company issued Intrexon shares valued at $1.5 million.
- Net loss included a non-cash warrant remeasurement charge of $4.70 million in Q3 and $5.35 million year to date. Warrants issued in the June public offering were classified as liabilities because of down-round and net-settlement provisions; their fair value rose as the share price increased.
- The June 2013 public unit offering generated $6.22 million net and included 6.77 million common shares and warrants. Common shares outstanding increased to 19.15 million from 11.17 million at December 31, 2012; outstanding warrants and options add potential dilution.
Outlook, programs and risks
- Management said existing cash, grant proceeds and anticipated New Jersey tax-credit certificate proceeds were expected to fund working capital and capital expenditures into the first quarter of 2015. This outlook is subject to funding and spending assumptions.
- For the next 12 months, the company expected approximately $12.4 million of R&D expenditure before grant reimbursements and approximately $9.1 million of contract and grant revenue, primarily to offset Vaccines/BioDefense R&D.
- The company reported approximately $34.6 million of active government grant and contract funding available through 2018. It also received BARDA and NIAID contracts for OrbeShield development, with options that could bring their stated maximum values to $26.3 million and $6.4 million, respectively; these amounts are conditional and spread over multiple years.
- Management’s development priorities included planned trials of SGX942 for oral mucositis and SGX203 for pediatric Crohn’s disease, and advancing OrbeShield, RiVax and other programs. Timelines and outcomes remain uncertain; the filing describes the products as investigational and dependent in part on grants, clinical results, regulatory progress and manufacturing development.
- Key risks include ongoing losses and cash burn, potential need for additional equity financing, clinical and regulatory failure or delay, dependence on government funding, and possible dilution. The company disclosed $356,300 of licensing-related commitments and $152,500 of lease and other obligations in its contractual-obligations schedule. Management reported effective disclosure controls and no additional risk factors beyond those in its 2012 Form 10-K.
Important facts for investors to verify
- Whether grant funding and the newly awarded OrbeShield contract options are available on the anticipated schedule and at the stated amounts.
- Whether cash burn, planned R&D spending and expected grant receipts support the stated runway into Q1 2015.
- The warrant terms, valuation assumptions and potential share dilution, including the effect of future stock-price changes on reported earnings.
- Clinical-trial progress, regulatory milestones and funding for SGX942, SGX203, OrbeShield and other development programs.
- Whether future financing or use of equity to compensate vendors and partners may materially dilute existing shareholders.